Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2332-2338

  Dai, Chia Yen ^a,b   Tseng, Tai Chung ^c,d   Wong, Grace Lai Hung ^e   Huang, Jee Fu ^a,b,f   Wong, Vincent Wai Sun ^e   Liu, Chun Jen ^d,g   Yu, Ming Lung ^a,b   Chuang, Wan Long ^a,b   Kao, Jia Horng ^d,g   Yuen Chan, Henry Lik ^e   Chen, Ding Shinn ^d,g  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

HBV DNA; Hepatitis b e antigen; Nucleos(t)ide analogues

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

HBV DNA; HEPATITIS B E ANTIGEN; NUCLEOS(T)IDE ANALOGUES;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84888792841     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt193     Document Type: Article

References (35)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669-79.
3. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir Res 2004; 64: 1-15.
4. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-93.
5. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
7. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
9. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
10. Yang JF, Lin CI, Huang JF et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010; 26: 461-9.
11. Dai CY, Chuang WL, Ho CK et al. Hepatitis C viremia and serum lipid levels: a clue from an epidemiology study. J Hepatol 2009; 50: 422-3.
12. Chen CH, Yang PM, Huang GT et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 148-55.
13. Chan HL, Chui AK, Lau WY et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-7.
14. Liu SF, Hsieh MH, Hou NJ et al. Hepatitis B virus genotyping by enzymelinked immunosorbent assay in Taiwan. Hepatol Int 2010; 4: 601-7.
15. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histologic liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-12.
16. Yu ML, Lee CM, Chuang WL et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010; 202: 86-92.
17. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
18. Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statementon themanagement of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
19. Zoulim F, Poynard T, Degos F et al. Aprospective studyof the evolution of lamivudineresistancemutations in patients with chronic hepatitisBtreated with lamivudine. J Viral Hepat 2006; 13: 278-88.
20. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 Suppl 1: S2-19.
21. Di Bisceglie AM, Lai CL, Gane E et al. Telbivudine globe trial:maximalearly HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: 230A.
22. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
23. Cooksley G, Manns M, Lau GKK et al. Effect of genotype and other baseline factors on response to peginterferon a-2a (40 kDa) (PEGASYSw) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005; 42 Suppl 2: 30-1.
24. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003; 39 Suppl 1: S111-5.
25. Chien RN, Yeh CT, Tsai SL et al. The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
26. Chan HL, Wong VW, Wong GL et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
27. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-9.
28. Brunetto MR, Oliveri F, Colombatto P et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
29. Chan HL, Wong VW, Chim AM et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-31.
30. Sonneveld MJ, Rijckborst V, Boucher CA et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
31. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol 2010; 25: 1498-506.
32. Piratvisuth T, Lau GKK, Marcellin P et al. On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months post-treatment in HBsAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40 KD] (PEGASYS). Hepatol Int 2010; 4: 152 (PP211).
33. Cai W, Xie Q, An B et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-6.
34. Liang Y, Jiang J, Su M et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
35. Chan HL, Wong GL, Chim AM et al. Prediction of off-treatment sustained response to lamivudine byserum hepatitis B surface antigen quantification in patients with negative hepatitis B e antigen. Antivir Ther 2011; 16: 1249-57.